Skip to search formSkip to main contentSkip to account menu

cositecan

Known as: (4S)-4-Ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dione, Karenitecin 
A synthetic silicon-containing agent related to camptothecin with antineoplastic properties. Cositecan stabilizes the cleavable complex between… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BNP 1350

Broader (1)

Camptothecin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Karenitecin ( BNP 1350 ) radiosensitizes glioma cells with an associated increase in caspase activation and reactive oxygen species
The prognosis for patients with high-grade glioma remains dismal illustrating the need for the development of chemotherapeutic… 
2017
2017
Karenitecin (BNP1350) radiosensitizes glioma cells with an associated increase in caspase activation and reactive oxygen species.
The prognosis for patients with high-grade glioma remains dismal illustrating the need for the development of chemotherapeutic… 
2016
2016
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
The poor prognosis of malignant glioma patients highlights the need to develop low toxicity, tumor specific agents with the… 
2016
2016
Evaluation of potential cytochrome p450 and plasma protein binding drug interactions for the class of camptothecins
Purpose: To compare the potential metabolism and protein binding interactions with selected camptothecin agents. Methods… 
2008
2008
Phase II multicenter open‐label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
The topoisomerase I agents are established as a therapy in recurrent ovarian cancer. Karenitecin, an analog of topotecan with… 
2008
2008
Gateways to clinical trials.
Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following… 
2006
2006
Valproic acid sensitizes human melanoma cells to karenitecin in vitro and in vivo
Proc Amer Assoc Cancer Res, Volume 47, 2006 1355 Melanoma continues to be a difficult disease to treat and rarely achieves a… 
2006
2006
Effect of plasma protein binding on the in vitro activity of Karenitecin™ (BNP1350) and other camptothecins.
5543 During the last 30 years, camptothecins have emerged as an important new class of anti-tumor drugs. Two water soluble… 
Review
2005
Review
2005
Phase II Trial of Karenitecin in PatientswithMalignantMelanoma : Clinical andTranslational Study
Purpose: A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacyand tolerability… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)